Helix BioPharma Corp. (TSE:HBP – Get Free Report) reached a new 52-week low on Thursday . The stock traded as low as C$0.76 and last traded at C$0.82, with a volume of 7026 shares. The stock had previously closed at C$1.10.
Helix BioPharma Stock Performance
The stock has a market cap of C$40.20 million, a P/E ratio of -5.50 and a beta of -0.84. The firm has a 50 day moving average of C$1.19 and a two-hundred day moving average of C$0.59. The company has a debt-to-equity ratio of 773.67, a quick ratio of 1.04 and a current ratio of 0.74.
About Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Featured Articles
- Five stocks we like better than Helix BioPharma
- What is a support level?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- 3 Warren Buffett Stocks to Buy Now
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- How to Calculate Stock Profit
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
